About this trial
This intervention will focus on stimulant-using men at high risk for HIV who are in need of tailored behavioral interventions to mitigate co-occurring stimulant use and HIV risk in the era of pre-exposure prophylaxis (PrEP). The study is a pilot randomized controlled trial to evaluate the adaptation, feasibility, acceptability, and preliminary efficacy of a behavioral intervention.
Eligibility criteria
Qualifiers
be 18 years of age or older;
be sexually active cisgender men at high risk for HIV (foreign and US-born, residing in the US)-reporting any condomless anal sex (CAS) in the past three months with a man;
report use of stimulant (i.e., methamphetamine, powder cocaine, or crack-cocaine) at least one day in the past three or six month;
have HIV-negative serostatus;
Disqualifiers
display diminished capacity to consent (e.g., cognitive impairment); or
severe psychiatric symptoms (e.g., psychosis) that require more intensive treatment;
if they are HIV positive or living with HIV;
if they are already taking PrEP; and
Trial design
Treatments tested in this trial
- Tailored Positive Affect Intervention
- Contingency Management
Treatment groups
Locations
Sponsors and collaborators
University of Florida
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator